View More View Less
  • 1 Pécsi Tudományegyetem, Pécs
  • 2 Semmelweis Egyetem, Budapest
  • 3 Nyírő Gyula Országos Pszichiátriai és Addiktológiai Intézet, Budapest
Open access

Absztrakt:

Mind a depresszió, mind a daganatos kórképek népbetegségek, melyek ráadásul sokszor komorbid módon fordulnak elő. Nem szisztematikus (narratív) összefoglaló tanulmányunkban röviden áttekintjük a depresszió és a malignus betegségek közti epidemiológiai összefüggéseket, melyek kapcsán elmondható, hogy 1) a depresszió előfordulási gyakorisága daganatos betegekben jóval meghaladja az átlagpopulációban mérhető értékeket; 2) depressziós páciensekben gyakrabban alakul ki malignus megbetegedés, és 3) a depresszió növeli a daganatspecifikus mortalitást. Az epidemiológiai összefüggések kapcsán röviden tárgyaljuk a daganatos betegek suicid halálozását is. Ezenkívül összefoglaljuk a két kórállapot gyakori együttállásának lehetséges etiológiai magyarázatait, ennek részeként azokat a biológiai és pszichológiai mechanizmusokat, amelyek magyarázhatják, hogy a depresszió (és/vagy annak kezelése) hogyan vezethet daganatok kialakulásához és vice versa. Végül röviden kitérünk még a depresszió szűrésének és kezelésének aspektusaira a daganatos betegek körében, megállapítva, hogy tekintettel a daganatos betegek között a depresszió aluldiagnosztizáltságára, az onkológiai ellátásban javasolt a depresszió szűrése, felhíva a figyelmet arra, hogy a szűrésnek csak akkor van létjogosultsága, ha a kiszűrt pozitív esetek pszichiáterhez való eljutása (ahol megtörténhet a klinikai diagnózis felállítása és valamiféle antidepresszív kezelés elindítása) biztosított. Orv Hetil. 2020; 161(22): 908–916.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Malhi GS, Mann JJ. Depression. Lancet 2018; 392: 2299–2312.

  • 2

    Merikangas KR, Rihmer Z. Mood disorders: epidemiology. In: Sadock BJ, Sadock VA, Ruiz P. (eds.) Kaplan and Sadock’s Comprehensive Textbook of Psychiatry (10th edition). Wolters Kluwer, Philadelphia, PA, 2017; pp. 1614–1619.

  • 3

    Liu Q, He H, Yang J, et al. Changes in the global burden of depression from 1990 to 2017: findings from the Global Burden of Disease study. J Psychiatr Res. 2019 Aug 10. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 4

    Wang YH, Li JQ, Shi JF, et al. Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies. Mol Psychiatry 2019 Nov 19. [Epub ahead of print] Available from: https://doi.org/10.1038/s41380-019-0595-x [accessed: February 23, 2020].

  • 5

    Szádóczky E, Papp Z, Vitrai J, et al. Prevalence of mood and anxiety disorders in the Hungarian adult population. [A hangulat- és szorongásos zavarok előfordulása a felnőtt magyar lakosság körében.] Orv Hetil. 2000; 141: 17–22. [Hungarian]

  • 6

    GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1603–1658. [Correction: Lancet 2017; 389(10064): e1.]

  • 7

    Moller HJ, Bitter I, Bobes J, et al. Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. Eur Psychiatry 2012; 27: 114–128.

  • 8

    Kovács K, Bálint L. Mortality. In: Monostori J, Őri P, Spéder Z. (eds.) Demographic portrait 2018. [Halandóság. In: Monostori J, Őri P, Spéder Zs. (szerk.) Demográfiai portré 2018.] KSH Népességtudományi Kutatóintézet, Budapest, 2018; pp. 147–175. [Hungarian]

  • 9

    Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394–424.

  • 10

    Gilman SE, Sucha E, Kingsbury M, et al. Depression and mortality in a longitudinal study: 1952–2011. CMAJ 2017; 189: E1304–E1310.

  • 11

    Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry 2015; 72: 334–341. [Error in figure caption: JAMA Psychiatry 2015; 72: 736.] [Error in table footnote: JAMA Psychiatry 2015; 72: 1259.]

  • 12

    Chang CK, Hayes RD, Perera G, et al. Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. PLoS ONE 2011; 6: e19590.

  • 13

    Zivin K, Ilgen MA, Pfeiffer PN, et al. Early mortality and years of potential life lost among Veterans Affairs patients with depression. Psychiatr Serv. 2012; 63: 823–826.

  • 14

    Laursen TM, Musliner KL, Benros ME, et al. Mortality and life expectancy in persons with severe unipolar depression. J Affect Disord. 2016; 193: 203–207.

  • 15

    Pitman A, Suleman S, Hyde N, et al. Depression and anxiety in patients with cancer. BMJ 2018; 361: k1415.

  • 16

    Mitchell AJ, Chan M, Bhatti H, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011; 12: 160–174.

  • 17

    Rivest J, Levenson J. Clinical features, assessment, and diagnosis of unipolar depressive disorders in patients with cancer. In: Silver JM, Block SD. (eds.) UpToDate. Waltham, MA, 2019.

  • 18

    Krebber AM, Buffart LM, Kleijn G, et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psychooncology 2014; 23: 121–130.

  • 19

    Walker J, Hansen CH, Martin P, et al. Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross-sectional analysis of routinely collected clinical data. Lancet Psychiatry 2014; 1: 343–350.

  • 20

    Niedzwiedz CL, Knifton L, Robb KA, et al. Depression and anxiety among people living with and beyond cancer: a growing clinical and research priority. BMC Cancer 2019; 19: 943.

  • 21

    Caruso R, Nanni MG, Riba M, et al. Depressive spectrum disorders in cancer: prevalence, risk factors and screening for depression: a critical review. Acta Oncol. 2017; 56: 146–155.

  • 22

    Mallet J, Huillard O, Goldwasser F, et al. Mental disorders associated with recent cancer diagnosis: results from a nationally representative survey. Eur J Cancer 2018; 105: 10–18.

  • 23

    Lu D, Andersson TM, Fall K, et al. Clinical diagnosis of mental disorders immediately before and after cancer diagnosis: a nationwide matched cohort study in Sweden. JAMA Oncol. 2016; 2: 1188–1196. [Correction: JAMA Oncol. 2016; 2: 1244.]

  • 24

    Mallet J, Dubertret C, Huillard O. Clinical diagnosis of mental disorders before cancer diagnosis. JAMA Oncol. 2017; 3: 565–566.

  • 25

    Scott KM, Lim C, Al-Hamzawi A, et al. Association of mental disorders with subsequent chronic physical conditions: world mental health surveys from 17 countries. JAMA Psychiatry 2016; 73: 150–158.

  • 26

    Jia Y, Li F, Liu YF, et al. Depression and cancer risk: a systematic review and meta-analysis. Public Health 2017; 149: 138–148.

  • 27

    Mitchell AJ. Why doesn’t depression treatment improve cancer survival? Lancet Psychiatry 2018; 5: 289–291.

  • 28

    Ahn HK, Bae JH, Ahn HY, et al. Risk of cancer among patients with depressive disorder: a meta-analysis and implications. Psychooncology 2016; 25: 1393–1399.

  • 29

    Davis LE, Bogner E, Coburn NG, et al. Stage at diagnosis and survival in patients with cancer and a pre-existing mental illness: a meta-analysis. J Epidemiol Community Health 2020; 74: 84–94.

  • 30

    Pinquart M, Duberstein PR. Depression and cancer mortality: a meta-analysis. Psychol Med. 2010; 40: 1797–1810.

  • 31

    Yang L, Korhonen K, Moustgaard H, et al. Pre-existing depression predicts survival in cardiovascular disease and cancer. J Epidemiol Community Health 2018; 72: 617–622.

  • 32

    Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 2009; 115: 5349–5361.

  • 33

    Zhu J, Fang F, Sjölander A, et al. First-onset mental disorders after cancer diagnosis and cancer-specific mortality: a nationwide cohort study. Ann Oncol. 2017; 28: 1964–1969.

  • 34

    Ko A, Kim K, Sik Son J, et al. Association of pre-existing depression with all-cause, cancer-related, and noncancer-related mortality among 5-year cancer survivors: a population-based cohort study. Sci Rep. 2019; 9: 18334.

  • 35

    Rihmer Z. Suicide risk in mood disorders. Curr Opin Psychiatry 2007; 20: 17–22.

  • 36

    Fujisawa D. Depression in cancer care. Keio J Med. 2018; 67: 37–44.

  • 37

    Henson KE, Brock R, Charnock J, et al. Risk of suicide after cancer diagnosis in England. JAMA Psychiatry 2019; 76: 51–60.

  • 38

    Wang SM, Chang JC, Weng SC, et al. Risk of suicide within 1 year of cancer diagnosis. Int J Cancer 2018; 142: 1986–1993.

  • 39

    Saad AM, Gad MM, Al-Husseini MJ, et al. Suicidal death within a year of a cancer diagnosis: a population-based study. Cancer 2019; 125: 972–979.

  • 40

    Carota A, Bogousslavsky J. Catastrophe reaction and emotionalism. Front Neurol Neurosci. 2018; 41: 50–60.

  • 41

    Barnes AF, Yeo TP, Leiby B, et al. Pancreatic cancer-associated depression: a case report and review of the literature. Pancreas 2018; 47: 1065–1077.

  • 42

    Hartung TJ, Brähler E, Faller H, et al. The risk of being depressed is significantly higher in cancer patients than in the general population: prevalence and severity of depressive symptoms across major cancer types. Eur J Cancer 2017; 72: 46–53.

  • 43

    Gross AL, Gallo JJ, Eaton WW. Depression and cancer risk: 24 years of follow-up of the Baltimore Epidemiologic Catchment Area sample. Cancer Causes Control 2010; 21: 191–199.

  • 44

    Smith HR. Depression in cancer patients: pathogenesis, implications and treatment (Review). Oncol Lett. 2015; 9: 1509–1514.

  • 45

    Peeters F, Nicolson NA, Berkhof J. Levels and variability of daily life cortisol secretion in major depression. Psychiatry Res. 2004; 126: 1–13.

  • 46

    Tsai CJ, Chiu WC, Chen CJ, et al. Antidepressant prescription and risk of lung cancer: a nationwide case-control study. Pharmacopsychiatry 2019; 52: 134–141.

  • 47

    Huang J, Zhao D, Liu Z, et al. Repurposing psychiatric drugs as anti-cancer agents. Cancer Lett. 2018; 419: 257–265.

  • 48

    Lee HC, Chiu WC, Wang TN, et al. Antidepressants and colorectal cancer: a population-based nested case-control study. J Affect Disord. 2017; 207: 353–358.

  • 49

    Huo YL, Qiao JM, Gao S. Association between antidepressant medication use and epithelial ovarian cancer risk: a systematic review and meta-analysis of observational studies. Br J Clin Pharmacol. 2018; 84: 649–658.

  • 50

    Boursi B, Lurie I, Mamtani R, et al. Anti-depressant therapy and cancer risk: a nested case-control study. Eur Neuropsychopharmacol. 2015; 25: 1147–1157.

  • 51

    Reeves KW, Okereke OI, Qian J, et al. Depression, antidepressant use, and breast cancer risk in pre- and postmenopausal women: a prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2018; 27: 306–314.

  • 52

    Shoval G, Balicer RD, Feldman B, et al. Adherence to antidepressant medications is associated with reduced premature mortality in patients with cancer: a nationwide cohort study. Depress Anxiety 2019; 36: 921–929.

  • 53

    Machado MO, Veronese N, Sanches M, et al. The association of depression and all-cause and cause-specific mortality: an umbrella review of systematic reviews and meta-analyses. BMC Med. 2018; 16: 112.

  • 54

    Kisely S, Crowe E, Lawrence D. Cancer-related mortality in people with mental illness. JAMA Psychiatry 2013; 70: 209–217.

  • 55

    Machado MO, Oriolo G, Bortolato B, et al. Biological mechanisms of depression following treatment with interferon for chronic hepatitis C: a critical systematic review. J Affect Disord. 2017; 209: 235–245.

  • 56

    Kayser MS, Kohler CG, Dalmau J. Psychiatric manifestations of paraneoplastic disorders. Am J Psychiatry 2010; 167: 1039–1050.

  • 57

    Rooney AG. The Neuropsychiatry of brain tumors. In: Sadock BJ, Sadock VA, Ruiz P. (eds.) Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. Wolters Kluwer, Philadelphia, PA, 2017; pp. 489–507.

  • 58

    Nickel A, Thomalla G. Post-stroke depression: impact of lesion location and methodological limitations – a topical review. Front Neurol. 2017; 8: 498.

  • 59

    Alexopoulos GS. Depression in the elderly. Lancet 2005; 365: 1961–1970.

  • 60

    Caruso R, GiuliaNanni M, Riba MB, et al. Depressive spectrum disorders in cancer: diagnostic issues and intervention. A critical review. Curr Psychiatry Rep. 2017; 19: 33.

  • 61

    McDaniel JS, Musselman DL, Porter MR, et al. Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry 1995; 52: 89–99.

  • 62

    Practice guideline for the treatment of patients with major depressive disorder. 3rd edn. American Psychiatric Association, Washington, DC, 2010.

  • 63

    Ostuzzi G, Matcham F, Dauchy S, et al. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev. 2018; 4: CD011006.

  • 64

    Ramasubbu R, Taylor VH, Samaan Z, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. Ann Clin Psychiatry 2012; 24: 91–109.

  • 65

    Roy-Byrne PP. Management of psychiatric disorders in patients with cancer. In: Silver JM. (ed.) UpToDate. Waltham, MA, 2019.

  • 66

    Fulton JJ, Newins AR, Porter LS, et al. Psychotherapy targeting depression and anxiety for use in palliative care: a meta-analysis. J Palliat Med. 2018; 21: 1024–1037.

  • 67

    Haller H, Winkler MM, Klose P, et al. Mindfulness-based interventions for women with breast cancer: an updated systematic review and meta-analysis. Acta Oncol. 2017; 56: 1665–1676.

  • 68

    Sharpe M, Walker J, Holm Hansen C, et al. Integrated collaborative care for comorbid major depression in patients with cancer (SMaRT Oncology-2): a multicentre randomised controlled effectiveness trial. Lancet 2014; 384: 1099–1108.

  • 69

    Kawashima Y, Yonemoto N, Inagaki M, et al. Interventions to prevent suicidal behavior and ideation for patients with cancer: a systematic review. Gen Hosp Psychiatry 2019; 60: 98–110.

  • 70

    Mulick A, Walker J, Puntis S, et al. Is improvement in comorbid major depression associated with longer survival in people with cancer? A long-term follow-up of participants in the SMaRT Oncology-2 and 3 trials. J Psychosom Res. 2019; 116: 106–112.

  • 71

    Shim EJ, Lee JW, Cho J, et al. Association of depression and anxiety disorder with the risk of mortality in breast cancer: a National Health Insurance Service study in Korea. Breast Cancer Res Treat. 2020; 179: 491–498.

  • 72

    Zingone A, Brown D, Bowman ED, et al. Relationship between anti-depressant use and lung cancer survival. Cancer Treat Res Commun. 2017; 10: 33–39.

 

The author instructions are available in PDF.
Instructions for Authors in Hungarian HERE.

 

Mendeley citation style is available HERE.
  • Impact Factor (2019): 0.497
  • Scimago Journal Rank (2018): 0.176
  • SJR Hirsch-Index (2018): 20
  • SJR Quartile Score (2018): Q3 Medicine (miscellaneous)
  • Impact Factor (2018): 0.564
  • Scimago Journal Rank (2018): 0.193
  • SJR Hirsch-Index (2018): 18
  • SJR Quartile Score (2018): Q3 Medicine (miscellaneous)

Language: Hungarian

Founded in 1857
Publication: Weekly, one volume of 52 issues annually

Senior editors

Editor(s)-in-Chief: Papp Zoltán

Read the professional career of Papp Zoltán HERE.

 

Editorial Board

Click for the Editorial Board

Akadémiai Kiadó
Address: Prielle Kornélia u. 21-35. H-1117 Budapest, Hungary
Phone: (+36 1) 464 8235 ---- Fax: (+36 1) 464 8221
Email: orvosihetilap@akkrt.hu